MediciNova, Inc. (MNOV) News
Follow MediciNova, Inc. (MNOV) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 10 public stories across 5 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
MediciNova Stock Falls on Topline Results from Phase 2 Trial for Fatty Liver Disease Treatment
By Kelly CloonanShares of MediciNova declined after topline results from a Phase 2 trial for the company's potential treatment for hypertriglyceridemia and nonalcoholic fatty liver disease did not show statistical signif
EQUITY | Sep 28, 2026, 11:15 AM UTC
L
MediciNova (MNOV) Posts MN-001 Phase 2 Topline in NAFLD/T2DM
MediciNova reported Phase 2 topline data for MN-001 showing a statistically significant TG reduction at Week 4, significant increases in HDL-C and HDL-P, and numerical trends in liver fat and body weight; safety was gene
NEWS | Sep 28, 2026, 10:02 AM UTC
L
MediciNova Announces Topline Results from MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)
MN-001 showed statistically significant increases in HDL-C and HDL-P and significant early reduction in triglyceride, a reduction in body weight and a numerical improvement in liver fatLA JOLLA, Calif., Sept. 28, 2026 (G
NEWS | Sep 28, 2026, 10:01 AM UTC
L
MediciNova (MNOV) Completes LPLV in Double-Blind Phase of COMBAT-ALS
MediciNova completed the last patient, last visit in the double-blind portion of its Phase 2b/3 COMBAT-ALS trial of MN-166 and expects topline results by end-2026. Full study LPLV is expected in March 2027.Material Detai
NEWS | Sep 24, 2026, 10:02 AM UTC
L
MediciNova Announces Completion of Last Patient, Last Visit in the Double-Blind Portion of the Phase 2b/3 COMBAT-ALS Trial of MN-166 (Ibudilast)
LA JOLLA, Calif., Sept. 24, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market NASDAQ:MNOV and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), t
EQUITY | Sep 24, 2026, 10:01 AM UTC
L
MNOV - MediciNova Announces Completion of Last Patient, Last Visit in the Double-Blind Portion of the Phase 2b/3 COMBAT-ALS Trial of MN-166 (Ibudilast)
MNOV - MediciNova Announces Completion of Last Patient, Last Visit in the Double-Blind Portion of the Phase 2b/3 COMBAT-ALS Trial of MN-166 (Ibudilast)
NEWS | Sep 24, 2026, 10:00 AM UTC
M
Biotech shares hit 52-week highs; MNOV, RVTY, TLX jump
Several biotech stocks reached 52-week highs on Sept. 15, 2026, including MediciNova (MNOV), Revvity (RVTY), and Telix (TLX), with the report attributing strength to gains on certain clinical or financial results.
EQUITY | Sep 16, 2026, 05:36 AM UTC
L
MediciNova CEO to participate in two September investor conferences
MediciNova said Yuichi Iwaki, President and CEO, will participate in two investor conferences in September.
EQUITY | Sep 08, 2026, 10:08 AM UTC
L
MNOV - MediciNova to Participate in Two Investor Conferences in September
MNOV - MediciNova to Participate in Two Investor Conferences in September
EQUITY | Sep 08, 2026, 10:00 AM UTC
L
MediciNova terminates $30 million Yorkville standby equity facility
MediciNova will terminate its Standby Equity Purchase Agreement with Yorkville effective September 8, 2026, after notice on August 31, 2026. The $30.0 million facility signed July 30, 2025 produced sales of 175,000 share
EQUITY | Sep 02, 2026, 11:33 AM UTC